{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T20:59:45Z","timestamp":1789851585326,"version":"4.0.1"},"reference-count":47,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Little is known about public perceptions of antivirals for the treatment of mild-to-moderate COVID-19 in the United States (US). Our objective was to explore adult perceptions toward COVID-19 antivirals to improve outreach communications about antivirals for COVID-19.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>During July 2022, potential respondents \u226518 years were randomly sampled from a national opt-in internet panel, with oversampling of African Americans, Hispanics, and adults \u226565 years. Respondents were asked about sociodemographic factors, and knowledge, attitudes, and perceptions regarding COVID-19 antivirals. Results were weighted to represent the non-institutionalized US adult population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 1,155 respondents, 51% were female, 21% were 50\u221264 years, and 19% were \u226565 years. Compared to younger age groups, a greater proportion of adults \u226565 years were knowledgeable about COVID-19 antivirals and would take them if they tested positive or their doctor recommended them. Adults \u226565 years and those reporting immunosuppression or disability had the highest rates of willingness to take antivirals. For all groups, the proportion of people willing to take antivirals increased by &gt;20% if recommended by their doctor. Respondents in the 50\u221264 and \u226565 groups who were sure they would take COVID-19 antivirals were more likely to be fully vaccinated and less likely to be living in isolation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Groups that are less likely to have been vaccinated, those living in isolation, and those not sure about whether they would take an antiviral or not may be at risk for not receiving treatment to prevent severe COVID-19 outcomes. However, trust in doctor recommendations may be enough to overcome individual patient concerns about COVID-19 antivirals. Targeted initiatives to educate those at risk for severe COVID-19 outcomes about the effectiveness of antivirals may be needed to further lower this population\u2019s risk of severe COVID-19.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0335182","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T18:33:04Z","timestamp":1762885984000},"page":"e0335182","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Factors associated with knowledge, attitudes, and behaviors regarding antiviral medications for COVID-19 among US adults"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2373-2530","authenticated-orcid":true,"given":"E. Ivy","family":"Oyegun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muyiwa","family":"Ategbole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Jorgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Briggs Hagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Gutekunst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia H.","family":"Koumans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"pone.0335182.ref001","unstructured":"FDA. FDA approves first oral antiviral for treatment of COVID-19 in adults; 2023. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-oral-antiviral-treatment-covid-19-adults"},{"key":"pone.0335182.ref002","unstructured":"FDA. FDA revises letter of authorization for the emergency use authorization for Paxlovid; 2024. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-revises-letter-authorization-emergency-use-authorization-paxlovid"},{"issue":"12","key":"pone.0335182.ref003","first-page":"1290","article-title":"Budget impact of oral nirmatrelvir\/ritonavir in adults at high risk for progression to severe COVID-19 in the United States","volume":"29","author":"R Sandin","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"issue":"2","key":"pone.0335182.ref004","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0316529","article-title":"Severe outcomes of COVID-19 among adults with increased risk conditions: a population-based observational study","volume":"20","author":"S Dryden-Peterson","year":"2025","journal-title":"PLoS One"},{"key":"pone.0335182.ref005","unstructured":"FDA. Coronavirus (COVID-19) | drugs; 2023. Available from: https:\/\/www.fda.gov\/coronavirus-covid-19\/drugs"},{"key":"pone.0335182.ref006","unstructured":"IDSA. IDSA Guidelines on the treatment and management of patients with COVID-19. 2025."},{"issue":"7","key":"pone.0335182.ref007","article-title":"Infectious diseases society of america guidelines on the treatment and management of patients with COVID-19","volume":"78","author":"A Bhimraj","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"8","key":"pone.0335182.ref008","article-title":"Clinical features and outcomes of pediatric and adult patients hospitalized for coronavirus disease 2019: A comparison across age strata","volume":"11","author":"GX Li","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"pone.0335182.ref009","author":"CDC","year":"2025"},{"key":"pone.0335182.ref010","author":"EJ Topol","year":"2023"},{"issue":"1","key":"pone.0335182.ref011","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ajt.2022.12.004","article-title":"Paxlovid associated with decreased hospitalization rate among adults with COVID-19 - United States, April-September 2022","volume":"23","author":"MM Shah","year":"2023","journal-title":"Am J Transplant"},{"issue":"39","key":"pone.0335182.ref012","first-page":"876","article-title":"Differences in COVID-19 outpatient antiviral treatment among adults aged \u226565 years by age group \u2014 National Patient-Centered Clinical Research Network, United States, April 2022\u2013September 2023","volume":"73","author":"CM Quinlan","year":"2024","journal-title":"MMWR"},{"key":"pone.0335182.ref013","author":"D McNamar","year":"2023"},{"issue":"18","key":"pone.0335182.ref014","doi-asserted-by":"crossref","first-page":"545","DOI":"10.15585\/mmwr.mm6918e1","article-title":"Characteristics and clinical outcomes of adult patients hospitalized with COVID-19 - Georgia, March 2020","volume":"69","author":"JAW Gold","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"pone.0335182.ref015","author":"National Center for Immunization and Respiratory Diseases (NCIRD) DoVD"},{"key":"pone.0335182.ref016","author":"M Frellick","year":"2022"},{"issue":"3","key":"pone.0335182.ref017","doi-asserted-by":"crossref","first-page":"96","DOI":"10.15585\/mmwr.mm7103e1","article-title":"Racial and ethnic disparities in receipt of medications for treatment of COVID-19 - United States, March 2020-August 2021","volume":"71","author":"JL Wiltz","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"43","key":"pone.0335182.ref018","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.15585\/mmwr.mm7143a2","article-title":"Racial and ethnic disparities in outpatient treatment of COVID-19 - United States, January-July 2022","volume":"71","author":"TK Boehmer","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"12","key":"pone.0335182.ref019","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae666","article-title":"Perceptions and barriers to outpatient antiviral therapy for COVID-19 and influenza as observed by infectious disease specialists in North America: results of an Emerging Infections Network (EIN) survey, February 2024","volume":"11","author":"JB Singleton","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"10","key":"pone.0335182.ref020","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1093\/jamia\/ocac114","article-title":"Using Twitter data to understand public perceptions of approved versus off-label use for COVID-19-related medications","volume":"29","author":"Y Hua","year":"2022","journal-title":"J Am Med Inform Assoc"},{"issue":"10","key":"pone.0335182.ref021","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1377\/hlthaff.2023.01641","article-title":"A majority of Americans have no or low awareness of Paxlovid, the at-home COVID-19 treatment","volume":"43","author":"GK SteelFisher","year":"2024","journal-title":"Health Aff"},{"issue":"8","key":"pone.0335182.ref022","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0271212","article-title":"Knowledge, attitudes, and practices [KAP] toward COVID-19: a cross-sectional study in the New York Metropolitan Area and California Bay Area","volume":"17","author":"E Mark","year":"2022","journal-title":"PLoS One"},{"issue":"8","key":"pone.0335182.ref023","doi-asserted-by":"crossref","DOI":"10.2196\/38351","article-title":"Knowledge, attitude, practices, and vaccine hesitancy among the latinx community in southern California Early in the COVID-19 pandemic: cross-sectional survey","volume":"6","author":"SN Mehta","year":"2022","journal-title":"JMIR Form Res"},{"key":"pone.0335182.ref024","doi-asserted-by":"crossref","first-page":"856156","DOI":"10.3389\/fmed.2022.856156","article-title":"Knowledge, attitudes, and practices toward the prevention of COVID-19 in Bangladesh: a systematic review and meta-analysis","volume":"9","author":"A Raquib","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"pone.0335182.ref025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0267840","article-title":"Efficacy versus abundancy: comparing vaccination schemes","volume":"17","author":"O El Deeb","year":"2022","journal-title":"PLoS One"},{"issue":"24","key":"pone.0335182.ref026","doi-asserted-by":"crossref","first-page":"751","DOI":"10.15585\/mmwr.mm6924e1","article-title":"Public attitudes, behaviors, and beliefs related to COVID-19, stay-at-home orders, nonessential business closures, and public health guidance - United States, New York City, and Los Angeles, May 5-12, 2020","volume":"69","author":"ME Czeisler","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"pone.0335182.ref027","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40545-022-00422-2","article-title":"Assessing public knowledge, attitudes and determinants of third COVID-19 vaccine booster dose acceptance: current scenario and future perspectives","volume":"15","author":"AA Jairoun","year":"2022","journal-title":"J Pharm Policy Pract"},{"issue":"3","key":"pone.0335182.ref028","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/07448489809595631","article-title":"Reliability and validity of a self-efficacy instrument for protective sexual behaviors","volume":"47","author":"H Cecil","year":"1998","journal-title":"J Am Coll Health"},{"issue":"4","key":"pone.0335182.ref029","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1007\/s11135-011-9640-9","article-title":"Determinants of social desirability bias in sensitive surveys: a literature review","volume":"47","author":"I Krumpal","year":"2011","journal-title":"Qual Quant"},{"issue":"6","key":"pone.0335182.ref030","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.jadohealth.2017.01.003","article-title":"Use of a respondent-generated personal code for matching anonymous adolescent surveys in longitudinal studies","volume":"60","author":"L Ripper","year":"2017","journal-title":"J Adolesc Health"},{"issue":"5","key":"pone.0335182.ref031","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1007\/s12160-016-9789-5","article-title":"\u201cI don\u2019t know\u201d my cancer risk: implications for health behavior engagement","volume":"50","author":"EA Waters","year":"2016","journal-title":"Ann Behav Med"},{"issue":"6","key":"pone.0335182.ref032","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1177\/0272989X18785159","article-title":"Reducing \u201cI don\u2019t know\u201d responses and missing survey data: implications for measurement","volume":"38","author":"DC Denman","year":"2018","journal-title":"Med Decis Making"},{"key":"pone.0335182.ref033","first-page":"100223","article-title":"Reasons for being unsure or unwilling regarding intention to take COVID-19 vaccine among Japanese people: a large cross-sectional national survey","volume":"14","author":"S Nomura","year":"2021","journal-title":"Lancet Reg Health West Pac"},{"issue":"5","key":"pone.0335182.ref034","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10459-010-9222-y","article-title":"Likert scales, levels of measurement and the \u201claws\u201d of statistics","volume":"15","author":"G Norman","year":"2010","journal-title":"Adv Health Sci Educ Theory Pract"},{"issue":"2","key":"pone.0335182.ref035","article-title":"Everyone in action: addressing inequality through coordination","volume":"47","author":"ML Leal","year":"2025","journal-title":"J Public Health (Oxf)"},{"key":"pone.0335182.ref036","doi-asserted-by":"crossref","DOI":"10.5888\/pcd17.200322","article-title":"Social determinants of health-related needs during COVID-19 among low-income households with children","volume":"17","author":"SV Sharma","year":"2020","journal-title":"Prev Chronic Dis"},{"issue":"2","key":"pone.0335182.ref037","doi-asserted-by":"crossref","DOI":"10.2196\/19161","article-title":"Knowledge and behaviors toward COVID-19 among US residents during the early days of the pandemic: cross-sectional online questionnaire","volume":"6","author":"JM Clements","year":"2020","journal-title":"JMIR Public Health Surveill"},{"issue":"4","key":"pone.0335182.ref038","article-title":"Trends and predictors of COVID-19 information sources and their relationship with knowledge and beliefs related to the pandemic: nationwide cross-sectional study","volume":"6","author":"SH Ali","year":"2020","journal-title":"JMIR Public Health Surveill"},{"key":"pone.0335182.ref039","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.puhe.2020.06.030","article-title":"The enigma of health literacy and COVID-19 pandemic","volume":"185","author":"MMM Abdel-Latif","year":"2020","journal-title":"Public Health"},{"key":"pone.0335182.ref040","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.puhe.2022.03.012","article-title":"A meta-analysis of COVID-19 vaccine attitudes and demographic characteristics in the United States","volume":"207","author":"LY Dhanani","year":"2022","journal-title":"Public Health"},{"issue":"6","key":"pone.0335182.ref041","first-page":"239","article-title":"How to overcome hesitancy for COVID-19 and other vaccines","volume":"71","author":"NL Mayo","year":"2022","journal-title":"J Fam Pract"},{"key":"pone.0335182.ref042","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.pec.2022.09.013","article-title":"Impact of a physician recommendation on COVID-19 vaccination intent among vaccine hesitant individuals","volume":"106","author":"KA Fisher","year":"2023","journal-title":"Patient Educ Couns"},{"issue":"6","key":"pone.0335182.ref043","article-title":"Parent-provider communication of HPV vaccine hesitancy","volume":"141","author":"LA Shay","year":"2018","journal-title":"Pediatrics"},{"issue":"15","key":"pone.0335182.ref044","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19","volume":"386","author":"J Hammond","year":"2022","journal-title":"N Engl J Med"},{"key":"pone.0335182.ref045","article-title":"Determining a meaningful R-squared value in clinical medicine","author":"A Gupta","year":"2024","journal-title":"Acad Med Surg"},{"issue":"5","key":"pone.0335182.ref046","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1037\/0033-2909.133.5.859","article-title":"Sensitive questions in surveys","volume":"133","author":"R Tourangeau","year":"2007","journal-title":"Psychol Bull"},{"key":"pone.0335182.ref047","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/B978-0-12-590241-0.50006-X","article-title":"Measurement and control of response bias.","volume-title":"Measures of personality and social psychological attitudes","author":"DL. Paulhus","year":"1991"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0335182","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T18:33:12Z","timestamp":1762885992000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0335182"}},"subtitle":[],"editor":[{"given":"Lawrence Sena","family":"Tuglo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":47,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0335182","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]}}}